Inspira Technologies terminates equity financing facilities

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced the termination of two equity financing agreements on March 31. The medical device company ended its sales agreement with A.G.P./Alliance Global Partners, dated February 17, 2026, and its Standby Equity Purchase Agreement with YA II PN, Ltd., dated December 12, 2025.

The company delivered formal written notices to terminate both financing facilities. No outstanding obligations or further advances remain under either agreement, according to the press release.

Inspira Technologies stated the decision reflects its commitment to maintaining a disciplined capital structure as it prepares for its next strategic phase. The company did not provide additional details about future financing plans or strategic initiatives.

The Ra'anana, Israel-based company develops respiratory support and blood monitoring technologies. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass procedures in the United States and ECMO procedures outside the U.S.

You May Also Be Interested In

• Teva submits NDA for ecopipam to treat pediatric Tourette syndrome
• BCB Bancorp suspends quarterly cash dividend to preserve capital
• Akanda receives Nasdaq notice over stockholders' equity deficit